Clinical Immune Modulator™ is a versatile, synergistic, immune-modulating formula with independent laboratory and limited in vivo studies. Synergistic use of supplements provides a real advantage over single item immune nutraceuticals! Single item or limited fermentation products such as BRM4 or AHCC do not appear to possess the versatility of Clinical Immune Modulator™. Potent effects on NK cell function have been noted with Clinical Immune Modulator™ (in vitro).
IMMUNE MODULATION: AN OVERVIEW
The immune system is comprised of a complex cascade of “cognitive communications”. This complex body system is not modulated in a versatile manner by single dietary substances, botanicals or limited fermentation products. The product, Clinical Immune Modulator™ (Biodefense) has a complex formulation of many different natural substances to address the body’s immune cascade of events.
While NK cells have been identified to be of importance in the first line defense of the body against cancer and cells infected with viruses, there are many types of white blood cells which have variable responses in the cascades of immune biodefense. The product Clinical Immune Modulator™ was developed to both activate NK cells and it contributes variably to many other aspects of the immune cascade of events. The
emphasis is on holistic approaches (synergy).
EFFECTS ON NK CELLS SUMMARY:
In cultures of human lymphocytes, Clinical Immune Modulator™ (BioDefense)™ (Natural Clinician™) is an activator of human Natural Killer (NK) cells, and it was found to be active at doses where BRM4 (MGN3) has no measurable effect. When using the maximum dose of MGN-3 (BRM-4) tolerated by human lymphocytes in culture, an activation of ~60% of the NK cells occured. When using the maximum dose of Clinical Immune Modulator™ (BioDefense)™ tolerated by human lymphocytes, activation of over 90% of the NK cells occurred. (Gitte Jensen et. al.)
When diluting BRM4 (MGN3) 100-fold from maximum dose, in this context there is no longer a significant /NK activation. When diluting Clinical Immune Modulator™ 100-fold from maximum dose, a significant effect on NK activation occurred. These data implied greater potency of Clinical Immune Modulator™ (BioDefense)™, in this context.
IN VITRO: Both Clinical Immune Modulator™
(BioDefense)™ and MGN-3 (BRM4) activate NK cells in vitro, but Clinical Immune Modulator™ (BioDefense)™ appeared in this study, to be more potent, per gram, Clinical Immune Modulator™ (BioDefense)™ is a more potent inducer of NK cell activation, under the extraction methods and culture conditions used in this study performed in an independent immunoscience laboratory. (Gitte Jensen et. al.)
The use of Clinical Immune Modulator™ (BioDefense)™ to activate NK cells, results in a high expression of the marker CD69, as well as some CD25 expression. BRM4 was used to activate NK cells, only a moderate expression of CD69 results, even at maximum dosages of MGN-3, and only minimal, if any, expression of CD25 occured. Again, Clinical Immune Modulator™ (BioDefense)™ downstaged BRM4 (MGN3) in vitro on this CD expression.
Both Clinical Immune Modulator™ (BioDefense)™ and MGN-3 induce a transient reduction in the % NK cells in the blood circulation, which is explained by NK homing into tissue, as part of the immunosurveillance effects of NK cells. One may translate these data to suggest that Clinical Immune Modulator™ (BioDefense)™ enhances normal immunosurveillance.
A study was made of the NK cells in the circulation of a small number of volunteers before and at 2, 4, and 24 hours after consumption of a Clinical Immune Modulator™ (Bio-Defense)™ and BRM4 (MGN3). The 2 and 4-hour studies allowed monitoring of the transient homing of NK cells. This was paralleled by changes in expression of L-selectin and CD11b on many of the NK cells remaining in the blood circulation, which indicate that NK cells had recently rolled on the endothelium, in their attempt to home into tissue. However, the 24-hour time point only showed a normalization of NK cells in the circulation. This was expressed both as % NK cells, and as the phenotype of the NK cells (expression of L-selectin, CD11b, CD25, and CD69). This outcome was interpreted as due to mean the NK cells going into tissue after the person consumed Clinical Immune Modulator™ (BioDefense)™ and staying in the tissue or recirculated to other areas via the lymphatics, and these cells did not return to the blood circulation in significant amounts. Again, one may interpret these data as limited evidence of enhanced immunosurveillance in vivo. Further research is required.